Cardiovasc Prev Pharmacother.  2024 Oct;6(4):109-115. 10.36011/cpp.2024.6.e14.

Moyamoya disease: insights into the clinical implications of the RNF213 gene

• Ok T

• KMID: 2560382
• DOI: http://doi.org/10.36011/cpp.2024.6.e14

Abstract

Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by progressive stenosis of the terminal internal carotid arteries and the formation of compensatory collateral vessels, which appear as a “puff of smoke” on cerebral angiography. It is a significant cause of stroke in East Asia, with an incidence of 0.5 to 1.5 cases per 100,000 people annually. The etiology of MMD remains unclear; however, the identification of the RNF213 gene, particularly the R4810K variant, as a major susceptibility factor among the East Asian population, has provided crucial insights into the disease's pathophysiology and clinical manifestations. MMD typically presents with transient ischemic attacks, ischemic and hemorrhagic strokes, seizures, headaches, and cognitive deficits. Diagnostic criteria have evolved to emphasize advanced imaging techniques. Pathological features include fibrocellular intimal thickening, irregular undulation of the elastic lamina, and the formation of moyamoya vessels. The mutation in the RNF213 gene impairs the degradation of proteins involved in vessel development, leading to abnormal angiogenesis. Genotype-phenotype studies indicate that the RNF213 variant is associated with an earlier onset, transient ischemic attacks, infarctions, and involvement of the posterior cerebral artery, although its effects vary between regions. Additionally, the homozygous RNF213 variant consistently correlates with an earlier age of onset and a higher risk of cerebral infarction. However, further research is necessary to fully understand its long-term impacts and its relationship with revascularization outcomes. Ongoing research is crucial to fully comprehend the pathophysiology and genetics of MMD, improve prognostic predictions, and develop novel therapies.

Keyword

Moyamoya disease; Stroke; Cerebrovascular disorders; Genotype; Phenotype

Reference

1. Takeuchi K, Shimizu K. Hypoplasia of the bilateral internal carotid arteries. Brain Nerve. 1957; 9:37–43.

2. Uchino K, Johnston SC, Becker KJ, Tirschwell DL. Moyamoya disease in Washington State and California. Neurology. 2005; 65:956–8.

3. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011; 56:34–40.

4. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011; 6:e22542.

5. Bang OY, Chung JW, Kim DH, Won HH, Yeon JY, Ki CS, et al. Moyamoya disease and spectrums of RNF213 vasculopathy. Transl Stroke Res. 2020; 11:580–9.

6. Kim JS. Moyamoya disease: epidemiology, clinical features, and diagnosis. J Stroke. 2016; 18:2–11.

7. Kim T, Lee H, Bang JS, Kwon OK, Hwang G, Oh CW. Epidemiology of moyamoya disease in Korea: based on national health insurance service data. J Korean Neurosurg Soc. 2015; 57:390–5.

8. Zhang H, Zheng L, Feng L. Epidemiology, diagnosis and treatment of moyamoya disease. Exp Ther Med. 2019; 17:1977–84.

9. Kim JE, Pang CH. Diagnosis and treatment of adult moyamoya disease. J Korean Med Assoc. 2019; 62:577–85.

10. Ok T, Jung YH, Lee KY. Genotype-phenotype correlation of the RNF213 R4810K variant in moyamoya disease. J Stroke. 2023; 25:303–6.

11. Kuroda S, Fujimura M, Takahashi J, Kataoka H, Ogasawara K, Iwama T, et al. Diagnostic criteria for moyamoya disease: 2021 revised version. Neurol Med Chir (Tokyo). 2022; 62:307–12.

12. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012; 52:245–66.

13. Church EW, Bell-Stephens TE, Bigder MG, Gummidipundi S, Han SS, Steinberg GK. Clinical course of unilateral moyamoya disease. Neurosurgery. 2020; 87:1262–8.

14. Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK. Progression of unilateral moyamoya disease: a clinical series. Cerebrovasc Dis. 2006; 22:109–15.

15. Lee SC, Jeon JS, Kim JE, Chung YS, Ahn JH, Cho WS, et al. Contralateral progression and its risk factor in surgically treated unilateral adult moyamoya disease with a review of pertinent literature. Acta Neurochir (Wien). 2014; 156:103–11.

16. Ok T, Jung YH, Kim J, Park SK, Park G, Lee S, et al. RNF213 R4810K variant in suspected unilateral moyamoya disease predicts contralateral progression. J Am Heart Assoc. 2022; 11:e025676.

17. Park EK, Lee YH, Shim KW, Choi JU, Kim DS. Natural history and progression factors of unilateral moyamoya disease in pediatric patients. Childs Nerv Syst. 2011; 27:1281–7.

18. Smith ER, Scott RM. Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus. 2008; 24:E17.

19. Yeon JY, Shin HJ, Kong DS, Seol HJ, Kim JS, Hong SC, et al. The prediction of contralateral progression in children and adolescents with unilateral moyamoya disease. Stroke. 2011; 42:2973–6.

20. Zhang Q, Wang R, Liu Y, Zhang Y, Wang S, Cao Y, et al. Clinical features and long-term outcomes of unilateral moyamoya disease. World Neurosurg. 2016; 96:474–82.

21. Hayashi K, Suyama K, Nagata I. Clinical features of unilateral moyamoya disease. Neurol Med Chir (Tokyo). 2010; 50:378–85.

22. Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y. Incidence and clinical features of disease progression in adult moyamoya disease. Stroke. 2005; 36:2148–53.

23. Mineharu Y, Takagi Y, Takahashi JC, Hashikata H, Liu W, Hitomi T, et al. Rapid progression of unilateral moyamoya disease in a patient with a family history and an RNF213 risk variant. Cerebrovasc Dis. 2013; 36:155–7.

24. Kaku Y, Morioka M, Ohmori Y, Kawano T, Kai Y, Fukuoka H, et al. Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: is arterial constrictive remodeling a major pathogenesis? Acta Neurochir (Wien). 2012; 154:2151–7.

25. Kuroda S, Kashiwazaki D, Akioka N, Koh M, Hori E, Nishikata M, et al. Specific shrinkage of carotid forks in moyamoya disease: a novel key finding for diagnosis. Neurol Med Chir (Tokyo). 2015; 55:796–804.

26. Ryoo S, Cha J, Kim SJ, Choi JW, Ki CS, Kim KH, et al. High-resolution magnetic resonance wall imaging findings of Moyamoya disease. Stroke. 2014; 45:2457–60.

27. Yuan M, Liu ZQ, Wang ZQ, Li B, Xu LJ, Xiao XL. High-resolution MR imaging of the arterial wall in moyamoya disease. Neurosci Lett. 2015; 584:77–82.

28. Bang OY, Fujimura M, Kim SK. The pathophysiology of moyamoya disease: an update. J Stroke. 2016; 18:12–20.

29. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008; 7:1056–66.

30. Scholz B, Korn C, Wojtarowicz J, Mogler C, Augustin I, Boutros M, et al. Endothelial RSPO3 controls vascular stability and pruning through non-canonical WNT/Ca(2+)/NFAT signaling. Dev Cell. 2016; 36:79–93.

31. Zhu G, Chen H, Zhang W. Phenotype switch of vascular smooth muscle cells after siRNA silencing of filamin. Cell Biochem Biophys. 2011; 61:47–52.

32. Wen J, Sun X, Chen H, Liu H, Lai R, Li J, et al. Mutation of rnf213a by TALEN causes abnormal angiogenesis and circulation defects in zebrafish. Brain Res. 2016; 1644:70–8.

33. Kobayashi H, Yamazaki S, Takashima S, Liu W, Okuda H, Yan J, et al. Ablation of Rnf213 retards progression of diabetes in the Akita mouse. Biochem Biophys Res Commun. 2013; 432:519–25.

34. Sonobe S, Fujimura M, Niizuma K, Nishijima Y, Ito A, Shimizu H, et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: a susceptibility gene for moyamoya disease. Brain Res. 2014; 1552:64–71.

35. Bersano A, Guey S, Bedini G, Nava S, Herve D, Vajkoczy P, et al. Research progresses in understanding the pathophysiology of moyamoya disease. Cerebrovasc Dis. 2016; 41:105–18.

36. Bedini G, Blecharz KG, Nava S, Vajkoczy P, Alessandri G, Ranieri M, et al. Vasculogenic and angiogenic pathways in moyamoya disease. Curr Med Chem. 2016; 23:315–45.

37. Wang Y, Yang L, Wang X, Zeng F, Zhang K, Zhang Q, et al. Meta-analysis of genotype and phenotype studies to confirm the predictive role of the RNF213 p.R4810K variant for moyamoya disease. Eur J Neurol. 2021; 28:823–36.

38. Jiang X, Liu L, Ai S, Xie X, Deng J, Jiang Z, et al. Meta-analysis of the association between RNF213 polymorphisms and clinical features of moyamoya disease in Asian population. Clin Neurol Neurosurg. 2023; 231:107801.

39. Ishigami D, Miyawaki S, Imai H, Shimizu M, Hongo H, Dofuku S, et al. RNF213 p.Arg4810Lys heterozygosity in moyamoya disease indicates early onset and bilateral cerebrovascular events. Transl Stroke Res. 2022; 13:410–9.

40. Kim EH, Yum MS, Ra YS, Park JB, Ahn JS, Kim GH, et al. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease. J Neurosurg. 2016; 124:1221–7.

41. Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012; 78:803–10.

42. Nomura S, Yamaguchi K, Akagawa H, Kawashima A, Moteki Y, Ishikawa T, et al. Genotype-phenotype correlation in long-term cohort of Japanese patients with moyamoya disease. Cerebrovasc Dis. 2019; 47:105–11.

43. Wang Y, Zhang Z, Wei L, Zhang Q, Zou Z, Yang L, et al. Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese moyamoya disease. Neurology. 2020; 94:e678–86.

44. Ge P, Ye X, Liu X, Deng X, Wang R, Zhang Y, et al. Association between p.R4810K variant and long-term clinical outcome in patients with moyamoya disease. Front Neurol. 2019; 10:662.

45. Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One. 2012; 7:e48179.

46. Zhang Q, Liu Y, Zhang D, Wang R, Zhang Y, Wang S, et al. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance. J Neurosurg. 2017; 126:1106–13.

47. Ito M, Kawabori M, Sugiyama T, Tokairin K, Tatezawa R, Uchino H, et al. Impact of RNF213 founder polymorphism (p.R4810K) on the postoperative development of indirect pial synangiosis after direct/indirect combined revascularization surgery for adult Moyamoya disease. Neurosurg Rev. 2022; 45:2305–13.

48. Kawabori M, Ito M, Kazumata K, Tokairin K, Hatanaka KC, Ishikawa S, et al. Impact of RNF213 c.14576G>A variant on the development of direct and indirect revascularization in pediatric moyamoya disease. Cerebrovasc Dis. 2023; 52:171–6.

49. Tashiro R, Fujimura M, Katsuki M, Nishizawa T, Tomata Y, Niizuma K, et al. Prolonged/delayed cerebral hyperperfusion in adult patients with moyamoya disease with RNF213 gene polymorphism c.14576G>A (rs112735431) after superficial temporal artery-middle cerebral artery anastomosis. J Neurosurg. 2020; 135:417–24.